Internal medicine

Pathology

Cohort study

Idiopathic pulmonary fibrosis

Diffusing capacity

Oncology

DLCO

Interstitial lung disease

Lung

Hypersensitivity pneumonitis

Lung function

Cohort

Medicine

The Lancet Respiratory Medicine

17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment.

Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis